| Date | Title | Description |
| 17.09.2026 | Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study | The paper introduces three interconnected resources for the global scientific community:
LongevityBench, the first open benchmark designed to rigorously evaluate AI reasoning across multiple domains of aging biology;
Longevity-LLMs, a famil... |
| 16.09.2026 | CLOC Announces Industry-First Certification for Legal Operations Professionals | Legal Operations Certified Professional (LOCP) credential establishes the first rigorous, independently validated standard of competency for the legal operations profession
SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire-PRWeb/ -- CLOC (Corpor... |
| 15.09.2026 | Gaucher Disease Drugs Market to Reach $4.3 Billion by 2036 as Long-Term Treatment and New Type 3 Therapies Reshape Rare-Disease Care | Enzyme replacement therapy leads with 58% share while Type 1 Gaucher disease accounts for 67% of 2026 demand
ROCKVILLE, Md., September 15, 2026 — The Gaucher disease treatment landscape is entering a new phase as established enzyme replacem... |
| 10.09.2026 | PW Consulting: Global Sedative-Hypnotic Drug Market Hits $4.85B in 2025, Projected 5.85% CAGR to 2032 | Navigating the Global Sedative-Hypnotic Drug Market: Strategic Imperatives for 2026 and Beyond
The global healthcare landscape is undergoing a significant transformation, driven by an aging population, increasing prevalence of sleep disorde... |
| 07.09.2026 | Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks | First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment).
Firs... |
| 01.09.2026 | Weave Bio and Takeda Deploy AI Regulatory Automation Across 14 Global Programs | What You Should Know
AI-native regulatory software company Weave Bio announced a major enterprise collaboration with global biopharma leader Takeda to deploy its regulatory automation platform across 14 active drug development programs in m... |
| 25.08.2026 | Innovent Announces 2026 Interim Results and Business Updates | Transforming from Regional Leader to Global Premier:
A Clear Strategic Path for Growth and Globalization
SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biophar... |
| 14.08.2026 | Soticlestat Revived: Perceptive Advisors Bets FDA Rejected Trial Design, Not Drug Itself | By Benjamin Eddie
Published: Aug 14 2026, 4:49 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 11.08.2026 | Quantified Named One of the Fastest-Growing AI & Data Companies on the Inc. 5000 List for the Second Consecutive Year | For the second consecutive year, Quantified lands on the Inc. 5000 list, fueled by growing adoption among top global pharma companies looking to keep commercial teams compliant, certified, coached, and ready to perform.
AUSTIN, Texas, Aug. ... |
| 22.07.2026 | Лейкозу подобрали лекарство | Лейкозу подобрали лекарство «Фармасинтез» выведет на рынок оригинальный препарат от рака крови
«Фармасинтез» Викрама Пунии получил регистрационное удостоверение на «Сибкордию». Это препарат для лечения рака крови на основе вамотиниба, полно... |
| 21.07.2026 | Takeda's Dengue Vaccine (TAK-003) Becomes India's First Approved Dengue Vaccine, Bringing Prevention to One of the World's Most At-Risk Populations | The approval comes at a critical time for public health, as reported dengue cases in India have increased 11-fold in the past two decades[1]
Takeda's dengue vaccine (TAK-003) is the most extensively studied dengue vaccine, with long-term da... |
| 16.07.2026 | Protagonist Therapeutics Reports Granting of Inducement Awards | NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employmen... |
| 15.07.2026 | Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development | Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model
CAMBRIDGE, Mass. and TAIPEI, July 15, 2026 /PRNewswire/ -- ... |
| 14.07.2026 | Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities | SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion t... |
| 09.07.2026 | Immunotherapy Drugs Market to Reach $580.6 Billion by 2029 | The global Immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, at a robust CAGR of 15.3% during the forecast period. Market growth is driven by advancements in antibody engineering te... |
| 02.07.2026 | Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery | Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas
CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative ... |
| 01.07.2026 | Protagonist Therapeutics Reports Granting of Inducement Awards | NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment... |
| 30.06.2026 | Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China | SAN FRANCISCO and SUZHOU, China, June 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for... |
| 08.06.2026 | 2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline | SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 04.06.2026 | World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer an... | SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 01.06.2026 | 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC | IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confi... |
| 01.06.2026 | 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy... | After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC
IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant... |
| 29.05.2026 | Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines | SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 29, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agre... |
| 27.05.2026 | The Best Workplaces™ in Vietnam 2026 List Is Out | HO CHI MINH CITY, Vietnam, May 27, 2026 /PRNewswire/ -- After surveying 111,682 employees across Vietnam, one of the largest workplace studies ever conducted in the country, Great Place To Work® is proud to reveal the Best Workplaces™ in Vi... |
| 19.05.2026 | Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences | SAN FRANCISCO and SUZHOU, China, May 19, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 14.05.2026 | Degron Therapeutics: $40 Million Series A Extension Closed To Support Molecular Glue Degrader Clinical Development | Degron Therapeutics announced the closing of a $40 million Series A Extension financing round to support the continued clinical development of its molecular glue degrader pipeline. The financing round was led by LAPAM CAPITAL, with particip... |
| 13.05.2026 | Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions | SAN FRANCISCO and SUZHOU, China, May 13, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 07.05.2026 | Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer to Advance Global Scientific Strategy and Innovation | CAMBRIDGE, Mass., May 7, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company advancing biotherapeutic discovery through innovative technology platforms, today announced the app... |
| 20.04.2026 | Digital Health Funding Hits $7.4B in Q1 2026 Driven by AI Drug Discovery and M&A | What You Should Know
The Spending Boom: Healthcare now captures nearly half of all vertical AI spend, projected to hit $1.5 billion in 2025 (more than tripling from $450 million the year prior), according to the latest CB Insights State of ... |
| 17.04.2026 | World Hemophilia Day 2026 - April 17, 2026 - "Diagnosis: First step to care." | MONTREAL, April 17, 2026 /PRNewswire/ -- On April 17, 2026, the global inherited bleeding disorders community will come together on World Hemophilia Day to advocate for all inherited bleeding disorders. This year's theme of "Diagnosis:... |
| 03.04.2026 | Lilly покупает британского разработчика лекарства от расстройства сна за $7,8 млрд | Препарат Zepbound компании Eli Lilly & Co. помогает решать одну из самых сложных проблем здравоохранения нашего времени — ожирение. Теперь фармкомпания берется за еще одну серьезную проблему общественного здоровья: расстройства сна.
В с... |
| 02.04.2026 | CHIC 2026 Honors Landmark Deals and Financings at Annual Awards Gala | SHANGHAI, April 2, 2026 /PRNewswire/ -- The 12th Annual China Healthcare Investment Conference (CHIC 2026) capped the first day of its two-day program with a celebratory Awards Gala Dinner held at The Ritz-Carlton Hotel Pudong, Shanghai. Th... |
| 31.03.2026 | Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs | Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals.
Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness.
The deal is the latest from Lilly, which is using its GLP-1 windfall to place mo... |
| 24.03.2026 | Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC | Abivax CEO Marc de Garidel told CNBC that the terms of any future deal will be better after it releases data on a key trial in the second quarter.
Intense takeover rumors have surrounded the French biotech company for months, with analysts ... |
| 19.03.2026 | Tech Titan's Dual Impact: Google's Wiz Acquisition and Israeli Media Shake-Up | Google acquired cloud security giant Wiz for $32 billion. This massive deal bolsters Google's AI-powered cyber defense across multicloud environments. Concurrently, Wiz co-founder Assaf Rappaport spearheaded a tech consortium's acquisition ... |
| 19.03.2026 | Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China | SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Spec... |
| 16.03.2026 | Google Acquires Wiz | Google LLC acquired Wiz, a New York City-based provider of cloud and AI security platforms.
The amount of the deal was not reportedly USD32 billion.
With the deal, Google will expand its security ecosystem to provide a unified platform that... |
| 24.02.2026 | Mavatar Delivers New Data-Driven Resources to Advance Precision Medicine for IBD | Mavatar Delivers New Data-Driven Resources to Advance Precision Medicine for IBD
Tue, Feb 24, 2026 17:00 CET Report this content
Mavatar, a global specialist in AI and data-driven precision medicine solutions, announces a key milestone in i... |
| 21.02.2026 | Будь Uniqlo: сложность и простота в работах Сато Касива | Один из известнейших современных японских дизайнеров Сато Касива, автор как графических работ, так и архитектурных, родился в Токио в 1965 году. Учился и окончил Университет искусств Тама по профильной специальности. Долгое время работал в ... |
| 02.02.2026 | ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging | SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully convened ahead of J.P. Morgan 2026. ACROBiosystems, as a ... |
| 19.01.2026 | Chinese Innovative Drugs' Global Rise Is Hot Topic at JP Morgan Healthcare Conference | (Yicai) Jan. 19 -- Chinese innovative drugs were an unavoidable topic among participants at the 44th annual JP Morgan Healthcare Conference due to their growing importance in the global pharmaceutical industry, with discussion focusing on i... |
| 11.01.2026 | Engitix Secures $25M to Advance Cancer, Fibrosis Therapies | British biotech innovator Engitix recently secured a significant $25 million Series A extension. Netherton Investments, acting for Mike Platt, drove this key financing. The capital fuels Engitix’s advanced extracellular matrix (ECM)-targete... |
| 09.01.2026 | Engitix: $25 Million Series A Extension Closed To Advance ECM-Targeted Pipeline In Oncology and Fibrosis | Engitix Therapeutics announced it has closed a $25 million Series A extension financing led by Netherton Investments, a fund investing on behalf of Mike Platt, co-founder and managing director of BlueCrest Capital Management.
The company sa... |
| 08.01.2026 | London’s Engitix secures €21 million extension to advance ECM-targeted cancer and fibrosis therapies | Engitix, a British BioTech company targeting the extracellular matrix (ECM) to develop transformative therapies for cancer and fibrosis, today announced the closing of a €21 million ($25 million) Series A extension financing.
The financing ... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 15.12.2025 | Нобелевская премия-2025: кто главные бенефициары научных открытий ученых-лауреатов? | Нобелевскую премию вручают за самые передовые открытия — и, конечно, у них есть большой коммерческий потенциал. Право авторства и право на саму разработку — это несколько разные вещи, и возможность получить действительно высокую прибыль буд... |
| 15.12.2025 | DISCO Pharmaceuticals: €36 Million Seed Funding Raised And Mark Manfredi Named As CEO | DISCO Pharmaceuticals has appointed biotech executive Mark Manfredi, Ph.D., as chief executive officer and completed the final close of a €36 million seed financing round to advance its pipeline of surfaceome-targeted drug candidates for ha... |
| 14.12.2025 | Israeli cyber startup Armis nears deal to be sold to ServiceNow for up to $7b — report | Israeli-founded cybersecurity unicorn Armis Security is in advanced talks to be acquired by US software company ServiceNow Inc. in a deal that could be worth up to $7 billion, Bloomberg News reported over the weekend.
The report cited a num... |
| 12.12.2025 | Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity | After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly s... |
| 10.12.2025 | Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody | SAN FRANCISCO and SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 09.12.2025 | AI reshaping how patients are diagnosed, treated | A visitor engages in a conversation with an AI sleep health management expert about the recovery process for sleep disorder conditions during the 2025 World Artificial Intelligence Conference in Shanghai on July 29. CHEN YUYU/FOR CHINA DAIL... |
| 09.12.2025 | Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis | SAN FRANCISCO and SUZHOU, China, Dec. 9, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 09.12.2025 | How a rare drug made from scientists’ blood saves babies from botulism | Getting your Trinity Audio player ready...
By JONEL ALECCIA, Associated Press
When Alessandro Barbera was rushed to a California hospital with infant botulism in October, his father had barely heard of the disease, never mind the rare and c... |
| 07.12.2025 | Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List | SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 03.12.2025 | How Platform Engineers Transform Pharmaceutical Compliance from Burden to Business Advantage | Share
Share
Share
Share
Email
Nivedha Sampath’s nine-year journey from large-scale patient data migrations to leading global compliance infrastructure modernization in the pharmaceutical industry
More than 25% of FDA warning letters since 2... |
| 28.11.2025 | American Neurology Summit 2025 Achieves Major Success With Full Attendance and High Engagement | ANS2025 served as a national platform for neurologists, primary care clinicians, nurses, and researchers to engage in high-impact education on the latest advancements in neurological care. The hybrid CME/CE event featured expert sessions on... |
| 18.11.2025 | Beacon Biosignals Secures $86M to Revolutionize Brain Disorder Treatment | Beacon Biosignals landed $86M in Series B funding. They plan to use it to improve diagnostics and treatment using AI. Their neurotechnology targets brain disorders. The funding helps them expand and accelerate discovery. This positions them... |
| 16.11.2025 | Beacon Biosignals: $86 Million Series B Raised To Advance AI-Driven Neurodiagnostics And Precision Neuroscience | Beacon Biosignals has raised an oversubscribed $86 million Series B to accelerate the clinical adoption of AI-powered biomarkers for neurological and psychiatric disease, expand its precision medicine data platform, and scale its neurodiagn... |
| 13.11.2025 | Beacon Biosignals Raises $86M in Series B Funding | Beacon Biosignals, a Boston, MA-based neurotechnology company powering AI-driven diagnostics and precision medicines for the brain, raised $86m in Series B funding.
Backers included Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, ... |
| 08.11.2025 | Accipiter Biosciences Secures $12.7M Seed Funding, Revolutionizing Protein Therapies | Accipiter Biosciences, a Seattle biotech, exited stealth with $12.7 million in seed funding. The company pioneers de novo multifunctional protein therapeutics. Its computational platform designs novel biologics from scratch. These single mo... |
| 07.11.2025 | Accipiter Biosciences Raises $12.7M in Seed Financing | Accipiter Biosciences, a Seattle, WA-based biotechnology company developing de novo multifunctional biologics to treat complex diseases, raised $12.7M in Seed funding.
The round was co-led by Takeda and Flying Fish Partners, with participat... |
| 07.11.2025 | HKSTP Crowns EPIC 2025 Winner: Champion of HKSTP EPIC 2025 NEU Battery Materials from Singapore Triumphs at Hong Kong’s Flagship I&T Mega Event | A fresh roster of innovators, and increased sums of investment, had global innovators eyeing Hong Kong’s I&T capabilities
HONG KONG SAR – Media OutReach Newswire – 7 November 2025 – Hong Kong Science and Technology Parks Corporation (HK... |
| 07.11.2025 | Accipiter Biosciences: $12.7 Million Seed Funding Closed To Develop De Novo Protein Therapies | Accipiter Biosciences has emerged from stealth with $12.7 million in seed funding to advance a new class of de novo multifunctional protein therapeutics designed to treat complex diseases. The seed round was co-led by Takeda and Flying Fish... |
| 06.11.2025 | Weave Bio Launches HAQ Manager: AI Automation Accelerates Health Authority Question Responses | What You Should Know:
– Weave Bio, the leader in AI-native regulatory automation, today announced the launch of HAQ Manager, a breakthrough capability that applies artificial intelligence (AI) and workflow automation to accelerate responses... |
| 05.11.2025 | HKSTP Manifesting 20 Latest BFSI Tech and Translation of R&D at Hong Kong FinTech Week x StartmeupHK Festival 2025 | MoU signed by 4 entities in laying the groundwork for AI-powered solutions in Compliance
HONG KONG SAR – Media OutReach Newswire – 5 November 2025 – Hong Kong Science and Technology Parks Corporation (HKSTP) brought the HKSTP Pavilion to th... |
| 30.10.2025 | Innovent’s tie-up with Takeda tests investor faith in China’s biotech dream | Since early October, shares of China’s innovative drugmakers have trended downward. As investors quipped about the need for another major deal to restore confidence, one such event finally arrived.
On October 22, Innovent Biologics announce... |
| 29.10.2025 | BD Deals Emerge as New Favored Partnership Mode Among Chinese Biotech Startups | (Yicai) Oct. 29 -- Business development deals between Chinese biotech startups and overseas pharmaceutical firms are surging and evolving into more varied forms of partnership.
BD deals commonly involve startups licensing the regional or gl... |
| 27.10.2025 | Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 | The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group
DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP... |
| 22.10.2025 | Pharmaceutical, life science industries drive trade surge between Indiana and Portugal | Please subscribe to IBJ to decode this article.
oceaseeaaan varlteeaeenaselm f eeva.gylo tih ecucorc id srli fts ht aamTgduotfd np ioe hciin’aes wusodyeir epnlnitte r,aIih rprsssttdyinn eltt rheeogPepdftt
aaAsao orh edyi atdo.cias rhdefrc n... |
| 06.10.2025 | Taiwan Pavilion Fostering Collaborative Innovation in AI, Regenerative Medicine and CDMO at BioJapan 2025 | TAIPEI, Oct. 6, 2025 /PRNewswire/ -- The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), an organization focused on fostering Taiwan's biotech ecosystem, announced today that it will lead a delegation of 16 biotech ind... |
| 30.09.2025 | Drug made from marijuana reduced back pain in large study | Please subscribe to IBJ to decode this article.
uminex hgira np sop.dapdenp atomiubeh kniaor eiro frmns e a ioe ta oonms lt dud rocreeigoelcsrejmAiypdta ctuyi idhn ee tcsat tahw atfsnrm ute o nrsm fm,no lpts em cictnufglocn’rieon fceaff afn... |
| 26.09.2025 | European, Asian drugmaker shares drop after Trump imposes tariffs | European, Asian drugmaker shares drop after Trump imposes tariffs
By Gregor Hunter and Andrew SilverSeptember 26, 20256:58 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 The logo of... |
| 19.09.2025 | Paris-based Juisci raises €5.5 million to transform how healthcare professionals access scientific knowledge | France’s Juisci, a HealthTech startup that transforms the way healthcare professionals consume scientific knowledge, has secured €5.5 million in Seed funding in order to boost R&D, scale its team, and accelerate international expansion,... |
| 16.09.2025 | Bristol Myers Sells Out of First US Drugs Joint Venture in China | (Yicai) Sept. 16 -- Bristol Myers Squibb has sold its controlling stake in what was the first American ian pharmaceuticals joint venture to be set up in China, as part of the drugmaker’s repositioning of global resources and regional strate... |
| 10.09.2025 | SSON Research & Analytics Unveils 2025 Top 20 Most Admired Shared Services Organizations & Global Business Services | 2025 Top 20 Most Admired SSOs and GBS
SSON Research & Analytics, the global data analytics center of the Shared Services & Outsourcing Network (SSON), has announced the 2025 list of the Top 20 Most Admired Shared Services Organizati... |
| 08.09.2025 | Integra Therapeutics Raises €10.7M in Funding | Integra Therapeutics, a Barcelona, Spain-based gene writing tools provider, raised €10.7M in funding.
Backers included IC Fund (European Commission) and CDTI Innvierte (Government of Spain) and current investors (AdBio, Columbus, Invivo and... |
| 04.09.2025 | ArcaScience Secures $7M to Revolutionize Drug Evaluation with AI | ArcaScience secured $7M seed funding. This investment propels AI-driven drug benefit-risk evaluation. The company will expand US and UK operations, launching crucial patient solutions. Focus areas include pediatric brain cancer and dermatol... |
| 03.09.2025 | ArcaScience raises $7M to transform drug development with AI-driven insights | AI healthtech startup ArcaScience has raised $7 million in seed funding to expand in the US and UK, launch patient solutions, and advance safer drug evaluation.
The round was led by The Moon Venture, with participation from Pléiade Venture,... |
| 03.09.2025 | ArcaScience raises $7M to expand AI benefit risk platform in drug development
Send us a News Tip
EXTRACT THE SIGNAL FROM THE NOISE
Cookies | French artificial intelligence healthtech startup ArcaScience SAS revealed today that it has raised $7 million in new funding to expand into the U.S. and the U.K., launch a patient-facing solution for pediatric brain cancer and dermatologic... |
| 03.09.2025 | ArcaScience Raises $7M to Advance AI-Powered Drug Benefit-Risk Evaluation | What You Should Know:
– ArcaScience, a Paris, France-based AI Healthtech startup, has announced a $7M seed funding round led by The Moon Venture, with participation from Pléiade Venture, Plug&Play Ventures, Bpifrance, and AKKA Technolog... |
| 27.08.2025 | Fangzhou Posts Strong 1H Revenue and Profit as Physician Network and User Base Expand | HONG KONG, Aug. 27, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, reported a profitable first half of 2025, supported by an expanding us... |
| 25.08.2025 | Top 100 Semi-Finalists Set Sail for EPIC 2025 Grand Finale in Hong Kong | Reaches Record Global Participation with 85% Non-Local Startups
HONG KONG SAR – Media OutReach Newswire – 25 August 2025 – EPIC 2025 Presented by Cathay and HSBC has successfully concluded its transcontinental pitching sessions, narrowing d... |
| 12.08.2025 | ConnectiveRx Thought Leaders Share Insights on Point of Care Measurement, Drug Pricing Impact, and Future of Patient Access | ConnectiveRx
Joanne Biscardi, Kristine McGaughey, and Chris Dowd demonstrate company's deep expertise across patient support ecosystem
WHIPPANY, N.J., Aug. 12, 2025 /PRNewswire-PRWeb/ -- ConnectiveRx, a leading provider of technology-enable... |
| 07.08.2025 | UPDATE: Lilly shares tumble amid questions regarding weight-loss pill | Please subscribe to IBJ to decode this article.
artep gdsooe rdm fy nesenorygiast g1tsa4tpeanh natda sadloeot.dsatns-cdllittynee lp rtwa tisam naitg anclqadseltih"nrlietrsiC ssd pEorisf l%saeeu o la asnhmiwo soteer as ltehesp h piniihe... |
| 04.08.2025 | Narcolepsy Network Debuts The Listening Project to Give Voice to the Diverse Experiences of People Living with Narcolepsy and Idiopathic Hypersomnia | The Listening Project
Takeda Pharmaceuticals Sponsors "Living with Narcolepsy Type 1" Inaugural Session
CAMAS, Wash., Aug. 4, 2025 /PRNewswire-PRWeb/ -- Narcolepsy Network is pleased to introduce The Listening Project, an initiati... |
| 29.07.2025 | Trump’s pharmaceutical tariffs could affect some drugmakers more than others | President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and they may have a bigger impact on some drugmakers than others.
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-... |
| 08.07.2025 | Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer | Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer
Tue, Jul 08, 2025 08:00 CET Report this content
Lund, Sweden, 8 July 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that Dr. Richard Philipso... |
| 08.07.2025 | Narcolepsy Network Announces its 38th Annual Conference | A Weekend of Learning, Community and Hope
CAMAS, Wash., July 8, 2025 /PRNewswire-PRWeb/ -- Narcolepsy Network is delighted to announce its 38th Annual Conference, taking place Friday, October 24 through Sunday, October 26, 2025, at the Roya... |
| 20.06.2025 | The Fight Against Dengue and HIV: Community Spirit and Innovative Solutions | In the battle against public health crises, two recent developments shine a light on the power of community and innovation. Dengue fever and HIV are formidable foes, but collective action and groundbreaking treatments offer hope. Dengue fev... |
| 18.06.2025 | The Dawn of Radioligand Therapies: A New Era in Precision Oncology | In the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ... |
| 17.06.2025 | How kampung spirit and comics are powering the fight against dengue | Listen
5 min
New: You can now listen to articles.
This audio is generated by an AI tool.
What does a strong sense of kampung (community) spirit have to do with eradicating dengue? Quite a bit, it turns out. A collective mindset can help res... |
| 13.06.2025 | Indianapolis-based startup leans on connections to treat brain diseases | Please subscribe to IBJ to decode this article.
so" co7tniifn:wct=l l5m=/nne4bBc_omtI"/ioaedel"-_oii=ii0-edidC5a2ru["00-mca5ae=fud othmtwi1ga"e"3r"daletl0ca]nsene d vy.sdstiheip =loto jee6teo mpts m3t [c6i... |
| 12.06.2025 | Uniting for Impact: "United Against Dengue" Collaboration Launches to Elevate Education, Advocacy and Support across Asia | Led by The International Federation of Red Cross and Red Crescent Societies and Takeda, the regional collaboration is dedicated to supporting the World Health Organization (WHO) and ASEAN goal of eliminating preventable dengue deaths by 203... |
| 06.06.2025 | JPMorgan’s top biotech and pharma picks for the second half | - |
| 05.06.2025 | Takeda Ukraine & Bulgaria Earn #8 Global Ranking in Best Places to Work 2024 | LONDON, UK – Media OutReach Newswire – 5 June 2025 – Takeda, a global value-based, R&D-driven biopharmaceutical company, has been proudly recognized as one of the Top 10 Best Places to Work in the World for 2024, achieving the No. 8 glo... |
| 31.05.2025 | Vima Therapeutics: $60 Million Series A Secured For Advancing Oral Therapy For People With Dystonia And Movement Disorders | Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing led by Atlas Venture, with participation from Access Industries and Canaan.
Vima ... |
| 30.05.2025 | GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal | YONGIN, South Korea, May 30, 2025 /PRNewswire/ -- GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its investigational drug for Hunter Syndrome (MPS II)... |
| 14.05.2025 | BioCentury to Host Grand Rounds in Chicago: Where Translational Science Meets Investors and Dealmakers | Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D
CHICAGO–(BUSINESS WIRE)–May 14, 2025–
Top decision-makers from across the biopharma ecosystem will con... |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 25.04.2025 | A Lifeline for Hemophilia: Sanofi and Sobi's Renewed Commitment to Global Health | In a world where access to healthcare can be as elusive as a mirage, the partnership between Sanofi, Sobi, and the World Federation of Hemophilia (WFH) stands as a beacon of hope. On April 25, 2025, these organizations announced a significa... |
